Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease

Journal of Pineal Research

Volumn 38, Issue 1, 2005, Pages 10-16

  Savaskan, Egemen ^a   Ayoub, Mohammed A ^b   Ravid, Rivka ^c   Angeloni, Debora ^d   Fraschini, Franco ^e   Meier, Fides ^a   Eckert, Anne ^a   Müller Spahn, Franz ^a   Jockers, Ralf ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b INSTITUT COCHIN   (France)

^c NETHERLANDS BRAIN BANK   (Netherlands)

^d SCUOLA SUPERIORE SANT ANNA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer's disease; Hippocampus; Melatonin receptor; MT2

Indexed keywords

MELATONIN 2 RECEPTOR; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CELL STRAIN HEK293; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALE; NEUROLOGIC DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; ANTIBODY SPECIFICITY; CELL LINE; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; METABOLISM;

AGED; ALZHEIMER DISEASE; ANTIBODY SPECIFICITY; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; RECEPTOR, MELATONIN, MT2; RECOMBINANT PROTEINS;

EID: 12344268788     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2004.00169.x     Document Type: Article

References (44)

1. REITER RJ. Pineal melatonin: cell biology of its synthesis and its physiological interactions. Endocr Rev 1991; 12:151-180.
2. MOORE RY. Circadian rhythms: basic neurobiology and clinical applications. Annu Rev Med 1997; 48:253-266.
3. SAVASKAN E. Melatonin in aging and neurodegeneration. Drug Dev Res 2002; 56:482-490.
4. FOULKES NS, BORJIGIN J, SNYDER SH et al. Rhythmic transcription: the molecular basis of circadian melatonin synthesis. Trends Neurosci 1997; 20:487-492.
5. VON GALL C, STEHLE JH, WEAVER DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 2002; 309:151-162.
6. DUBOCOVICH ML. Melatonin is a potent modulator of dopamine release in the retina. Nature 1983; 306:782-784.
7. ALLEGRA M, REITER RJ, TAN DX et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
8. REITER RJ, CABRERA J, SAINZ JC et al. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and Parkinsonism. Ann N Y Acad Sci 1999; 890:471-485.
9. PAPPOLLA MA, CHYAN Y-J, POEGGELER B et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 2000; 107:203-231.
10. MONROE KK, WATTS SW. The vascular reactivity of melatonin. Gen Pharmacol 1998; 30:31-35.
11. SAVASKAN E, OLIVIERI G, BRYDON L et al. Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer's disease. Neurosci Lett 2001; 308:9-12.
12. 2 is present in the human cardiovascular system. J Pineal Res 2003; 35:40-44.
13. DRAZEN DL, NELSON RJ. Melatonin receptor subtype MT2 (Mel1b) and not mt1 (Mel1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity. Neuroendocrinology 2000; 74:178-184.
14. PAWLIKOWSKI M, WINCZYK K, KARASEK M. Oncostatic action of melatonin: facts and question marks. Neuroendocrinol Lett 2002; 23:24-29.
15. REPPERT SM, GODSON C, MAHLE CD et al. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995; 92:8734-8738.
16. REPPERT SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 1997; 12:528-531.
17. DUBOCOVICH ML, MASANA MI, BENLOUCIF S. Molecular pharmacology and function of melatonin receptor subtypes. In: Melatonin after Four Decades. Olcese J ed. Plenum Publishers/Kluwer Academic, New York, 2000; pp. 181-190.
18. REPPERT SM, WEAVER DR, EBISAWA T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13:1177-1185.
19. BRYDON L, ROKA F, PETIT L et al. Dual signaling of human Mella melatonin receptors via Gi2, Gi3, and Gq/11 proteins. Mol Endocrinol 1999; 13:2025-2038.
20. EBISAWA T, KARNE S, LERNER Mr et al. Expression cloning of a high affinity melatonin receptor from Xenopus dermal melanophores. Proc Natl Acad Sci USA 1994; 91:6133-6137.
21. REPPERT SM, WEAVER DR, CASSONE VM et al. Melatonin receptors are for the birds: molecular analysis of two receptor subtypes differentially expressed in chick brain. Neuron 1995; 15:1003-1015.
22. DREW JE, BARRETT P, MERCER JG et al. Localization of the melatonin-related receptor in the rodent brain and peripheral tissues. J Neuroendocrinol 2001; 13:453-458.
23. 1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport 1996; 8:109-112.
24. MAZZUCHELLI C PANNACCI M, NONNO R et al. The melatonin receptor in the human brain: cloning experiments and distribution studies. Mol Brain Res 1996; 39:117-126.
25. SAVASKAN E, WIRZ-JUSTICE A, OLIVIERI G et al. Distribution of melatonin MT1 receptor immunoreactivity in human retina. J Histochem Cytochem 2002; 50:519-525.
26. 2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 1998; 12:1211-1220.
27. 2 melatonin receptor in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol 2001; 280:C110-C118.
28. AL-GHOUL WM, HERMAN MD, DUBOCOVICH ML. Melatonin receptor subtype expression in human cerebellum. Neuroreport 1998; 9:4063-4068.
29. ANGELONI D, LONGHI R, FRASCHINI F. Production and characterization of antibodies directed against the human melatonin receptors Mel-1a (mt1) and Mel-1b (MT2). Eur J Histochem 2000; 44:199-204.
30. AYOUB MA, COUTURIER C, LUCAS-MEUNIER E et al. Monitoring of ligand-dependent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 2002; 277:21522-21528.
31. MCKHANN G, DRACHMAN D, FOLSTEIN M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-944.
32. RAVID R, SWAAB DF, KAMPHORST W et al. Brain banking in aging and dementia research - the Amsterdam experience. In: Progress in Alzheimer's and Parkinson's Disease. Fisher A, Yorshida M, Hanin I eds. Plenum Press, New York, 1998; pp. 277-286.
33. BRAAK H, BRAAK H. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82:239-259.
34. MESULAM MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999; 24:521-529.
35. SAVASKAN E, OLIVIERI G, MEIER F et al. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 2002; 32:59-62.
36. Duvernoy HM (ed.). The Human Hippocampus, Functional Anatomy, Vascularization and Serial Sections with MRI. Springer, Berlin, 1997.
37. OAKNIN-BENDAHAN S, ANIS Y, NIR I et al. Pinealectomy but not melatonin supplementation affects the diurnal variations in 125I-melatonin binding sites in the rat brain. J Basic Clin Physiol Pharmacol 1992; 3:253-268.
38. 1b receptors. Nat Neurosci 1999; 2:401-403.
39. MUSSHOFF U, RIEWENHERM D, BERGER E et al. Melatonin receptors in rat hippocampus: molecular and functional investigations. Hippocampus 2002; 12:165-173.
40. HOGAN MV, EL-SHERIF Y, WIERASZKO A. The modulation of neuronal activity by melatonin: in vitro studies on mouse hippocampal slices. J Pineal Res 2001; 30:87-96.
41. DUBOCOVICH ML. Pharmacology and function of melatonin receptors. FASEB J 1998; 2:2765-2773.
42. 3H]glutamate uptake and release in the golden hamster retina. J Neurochem 1996; 67:623-628.
43. ZHOU J-N, LIU R-Y, HEERIKHUIZE J et al. Alterations in the circadian rhythm of salivary melatonin begin during middle-age. J Pineal Res 2003; 34:11-16.
44. LIU R-Y, ZHOU J-N, HEERIKHUIZE J et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-ε4/4 genotype. J Clin Endocrinol Metab 1999; 84:323-327.